Age-Related Macular Degeneration Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025

Description

The global age-related macular degeneration (AMD) market was valued at USD 11.7 billion in 2024 and is projected to reach USD 23.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.0%. This growth is primarily driven by the increasing prevalence of age-related eye diseases, a growing geriatric population, and advancements in research and development activities aimed at finding innovative treatments. AMD, which leads to vision loss among the elderly, is pushing the demand for new therapies, including gene therapy and long-acting drugs. With a limited number of approved treatments and patents expiring for key drugs, the market presents significant opportunities for drug manufacturers and healthcare providers.

The increasing global awareness of AMD and its symptoms, coupled with a rise in funding for research and clinical trials, is boosting the demand for effective treatments. Furthermore, initiatives to improve early detection through regular eye exams are expected to support market growth.

Key Insights

The most significant driver of the AMD market is the rise in the elderly population, which is more susceptible to the condition. In the 60+ age group, the prevalence of AMD can reach up to 46%, with an increase in cases expected as global populations age. The market is also benefiting from heightened awareness of AMD due to various health initiatives, such as National AMD Awareness Month, which aims to raise awareness about the disease, its symptoms, and potential treatments.

Innovative treatment options, including long-acting anti-VEGF (vascular endothelial growth factor) drugs like Beovu and Vabysmo, are helping drive the growth of the market. These therapies are designed to reduce the frequency of intravitreal injections, offering a more convenient option for patients and improving treatment adherence. Gene therapies and improvements in delivery methods, such as vitreous implants, are also being developed to offer longer-lasting effects with fewer injections, contributing to the growth of the market.

Despite the growth potential, regulatory challenges remain a significant barrier to market expansion. The complex and stringent regulatory approval process for new drugs often leads to delays in market entry, and the high failure rate of investigational drugs further exacerbates these challenges. In addition, off-label drug use in AMD treatment, although controversial, adds complexity to the overall regulatory environment.

The market is also benefiting from a robust product pipeline, with several companies focusing on the development of innovative therapies for AMD. The increasing number of clinical trials and rising investments in gene therapy and anti-VEGF drugs are expected to significantly enhance the market's expansion over the next decade.

North America holds the largest share of the AMD market, driven by high healthcare expenditure, advanced healthcare infrastructure, and increasing awareness of age-related eye diseases. However, the Asia-Pacific region is expected to witness the fastest growth, owing to the expanding elderly population and rising healthcare investments in countries such as China and India.

Product Code: 10628

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by drug type
- 1.4.2. Market size breakdown, by disease type
- 1.4.3. Market size breakdown, by age group
- 1.4.4. Market size breakdown, by gender
- 1.4.5. Market size breakdown, by stages
- 1.4.6. Market size breakdown, by distribution channel
- 1.4.7. Market size breakdown, by region
- 1.4.8. Market size breakdown, by country
1.5. Market Data Reporting Unit
- 1.5.1. Value
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
5.2. Impact of COVID-19
5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview
6.2. Market Revenue, by Drug Type (2019-2030)
6.3. Market Revenue, by Disease Type (2019-2030)
6.4. Market Revenue, by Age Group (2019-2030)
6.5. Market Revenue, by Gender (2019-2030)
6.6. Market Revenue, by Stages (2019-2030)
6.7. Market Revenue, by Distribution Channel (2019-2030)
6.8. Market Revenue, by Region (2019-2030)

Chapter 7. North America Market

7.1. Overview
7.2. Market Revenue, by Drug Type (2019-2030)
7.3. Market Revenue, by Disease Type (2019-2030)
7.4. Market Revenue, by Age Group (2019-2030)
7.5. Market Revenue, by Gender (2019-2030)
7.6. Market Revenue, by Stages (2019-2030)
7.7. Market Revenue, by Distribution Channel (2019-2030)
7.8. Market Revenue, by Country (2019-2030)

Chapter 8. Europe Market

8.1. Overview
8.2. Market Revenue, by Drug Type (2019-2030)
8.3. Market Revenue, by Disease Type (2019-2030)
8.4. Market Revenue, by Age Group (2019-2030)
8.5. Market Revenue, by Gender (2019-2030)
8.6. Market Revenue, by Stages (2019-2030)
8.7. Market Revenue, by Distribution Channel (2019-2030)
8.8. Market Revenue, by Country (2019-2030)

Chapter 9. APAC Market

9.1. Overview
9.2. Market Revenue, by Drug Type (2019-2030)
9.3. Market Revenue, by Disease Type (2019-2030)
9.4. Market Revenue, by Age Group (2019-2030)
9.5. Market Revenue, by Gender (2019-2030)
9.6. Market Revenue, by Stages (2019-2030)
9.7. Market Revenue, by Distribution Channel (2019-2030)
9.8. Market Revenue, by Country (2019-2030)

Chapter 10. LATAM Market

10.1. Overview
10.2. Market Revenue, by Drug Type (2019-2030)
10.3. Market Revenue, by Disease Type (2019-2030)
10.4. Market Revenue, by Age Group (2019-2030)
10.5. Market Revenue, by Gender (2019-2030)
10.6. Market Revenue, by Stages (2019-2030)
10.7. Market Revenue, by Distribution Channel (2019-2030)
10.8. Market Revenue, by Country (2019-2030)

Chapter 11. MEA Market

11.1. Overview
11.2. Market Revenue, by Drug Type (2019-2030)
11.3. Market Revenue, by Disease Type (2019-2030)
11.4. Market Revenue, by Age Group (2019-2030)
11.5. Market Revenue, by Gender (2019-2030)
11.6. Market Revenue, by Stages (2019-2030)
11.7. Market Revenue, by Distribution Channel (2019-2030)
11.8. Market Revenue, by Country (2019-2030)

Chapter 12. U.S. Market

12.1. Overview
12.2. Market Revenue, by Drug Type (2019-2030)
12.3. Market Revenue, by Disease Type (2019-2030)
12.4. Market Revenue, by Age Group (2019-2030)
12.5. Market Revenue, by Gender (2019-2030)
12.6. Market Revenue, by Stages (2019-2030)
12.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 13. Canada Market

13.1. Overview
13.2. Market Revenue, by Drug Type (2019-2030)
13.3. Market Revenue, by Disease Type (2019-2030)
13.4. Market Revenue, by Age Group (2019-2030)
13.5. Market Revenue, by Gender (2019-2030)
13.6. Market Revenue, by Stages (2019-2030)
13.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 14. Germany Market

14.1. Overview
14.2. Market Revenue, by Drug Type (2019-2030)
14.3. Market Revenue, by Disease Type (2019-2030)
14.4. Market Revenue, by Age Group (2019-2030)
14.5. Market Revenue, by Gender (2019-2030)
14.6. Market Revenue, by Stages (2019-2030)
14.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 15. France Market

15.1. Overview
15.2. Market Revenue, by Drug Type (2019-2030)
15.3. Market Revenue, by Disease Type (2019-2030)
15.4. Market Revenue, by Age Group (2019-2030)
15.5. Market Revenue, by Gender (2019-2030)
15.6. Market Revenue, by Stages (2019-2030)
15.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 16. U.K. Market

16.1. Overview
16.2. Market Revenue, by Drug Type (2019-2030)
16.3. Market Revenue, by Disease Type (2019-2030)
16.4. Market Revenue, by Age Group (2019-2030)
16.5. Market Revenue, by Gender (2019-2030)
16.6. Market Revenue, by Stages (2019-2030)
16.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 17. Italy Market

17.1. Overview
17.2. Market Revenue, by Drug Type (2019-2030)
17.3. Market Revenue, by Disease Type (2019-2030)
17.4. Market Revenue, by Age Group (2019-2030)
17.5. Market Revenue, by Gender (2019-2030)
17.6. Market Revenue, by Stages (2019-2030)
17.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 18. Spain Market

18.1. Overview
18.2. Market Revenue, by Drug Type (2019-2030)
18.3. Market Revenue, by Disease Type (2019-2030)
18.4. Market Revenue, by Age Group (2019-2030)
18.5. Market Revenue, by Gender (2019-2030)
18.6. Market Revenue, by Stages (2019-2030)
18.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 19. Japan Market

19.1. Overview
19.2. Market Revenue, by Drug Type (2019-2030)
19.3. Market Revenue, by Disease Type (2019-2030)
19.4. Market Revenue, by Age Group (2019-2030)
19.5. Market Revenue, by Gender (2019-2030)
19.6. Market Revenue, by Stages (2019-2030)
19.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 20. China Market

20.1. Overview
20.2. Market Revenue, by Drug Type (2019-2030)
20.3. Market Revenue, by Disease Type (2019-2030)
20.4. Market Revenue, by Age Group (2019-2030)
20.5. Market Revenue, by Gender (2019-2030)
20.6. Market Revenue, by Stages (2019-2030)
20.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 21. India Market

21.1. Overview
21.2. Market Revenue, by Drug Type (2019-2030)
21.3. Market Revenue, by Disease Type (2019-2030)
21.4. Market Revenue, by Age Group (2019-2030)
21.5. Market Revenue, by Gender (2019-2030)
21.6. Market Revenue, by Stages (2019-2030)
21.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 22. Australia Market

22.1. Overview
22.2. Market Revenue, by Drug Type (2019-2030)
22.3. Market Revenue, by Disease Type (2019-2030)
22.4. Market Revenue, by Age Group (2019-2030)
22.5. Market Revenue, by Gender (2019-2030)
22.6. Market Revenue, by Stages (2019-2030)
22.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 23. South Korea Market

23.1. Overview
23.2. Market Revenue, by Drug Type (2019-2030)
23.3. Market Revenue, by Disease Type (2019-2030)
23.4. Market Revenue, by Age Group (2019-2030)
23.5. Market Revenue, by Gender (2019-2030)
23.6. Market Revenue, by Stages (2019-2030)
23.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 24. Brazil Market

24.1. Overview
24.2. Market Revenue, by Drug Type (2019-2030)
24.3. Market Revenue, by Disease Type (2019-2030)
24.4. Market Revenue, by Age Group (2019-2030)
24.5. Market Revenue, by Gender (2019-2030)
24.6. Market Revenue, by Stages (2019-2030)
24.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 25. Mexico Market

25.1. Overview
25.2. Market Revenue, by Drug Type (2019-2030)
25.3. Market Revenue, by Disease Type (2019-2030)
25.4. Market Revenue, by Age Group (2019-2030)
25.5. Market Revenue, by Gender (2019-2030)
25.6. Market Revenue, by Stages (2019-2030)
25.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 26. Saudi Arabia Market

26.1. Overview
26.2. Market Revenue, by Drug Type (2019-2030)
26.3. Market Revenue, by Disease Type (2019-2030)
26.4. Market Revenue, by Age Group (2019-2030)
26.5. Market Revenue, by Gender (2019-2030)
26.6. Market Revenue, by Stages (2019-2030)
26.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 27. South Africa Market

27.1. Overview
27.2. Market Revenue, by Drug Type (2019-2030)
27.3. Market Revenue, by Disease Type (2019-2030)
27.4. Market Revenue, by Age Group (2019-2030)
27.5. Market Revenue, by Gender (2019-2030)
27.6. Market Revenue, by Stages (2019-2030)
27.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 28. U.A.E. Market

28.1. Overview
28.2. Market Revenue, by Drug Type (2019-2030)
28.3. Market Revenue, by Disease Type (2019-2030)
28.4. Market Revenue, by Age Group (2019-2030)
28.5. Market Revenue, by Gender (2019-2030)
28.6. Market Revenue, by Stages (2019-2030)
28.7. Market Revenue, by Distribution Channel (2019-2030)

Chapter 29. Competitive Landscape

29.1. List of Market Players and their Offerings
29.2. Competitive Benchmarking of Key Players
29.3. Product Benchmarking of Key Players
29.4. Recent Strategic Developments

Chapter 30. Company Profiles

30.1. Bayer AG
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
30.2. Novartis AG
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
30.3. Pfizer Inc.
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
30.4. F. Hoffmann-La Roche Ltd.
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
30.5. Regeneron Pharmaceuticals Inc.
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
30.6. Bausch Health Companies Inc.
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
30.7. Amgen Inc.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
30.8. AbbVie Inc.
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
30.9. REGENXBIO INC.
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
30.10. Outlook Therapeutics, Inc.
- 30.10.1. Business overview
- 30.10.2. Product and service offerings
- 30.10.3. Key financial summary

Chapter 31. Appendix

31.1. Abbreviations
31.2. Sources and References
31.3. Related Reports

Age-Related Macular Degeneration Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2032)